Wan-Shan Chen

CIK: 0002001438

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (33.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)1 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BLTE

BELITE BIO, INC

Director

Discretionary Trading P&L

Holdings

Transaction History (3 total)

BLTE
BELITE BIO, INC
Sep 24, 2026
In-the-Money(X)
Direct
13.8K shares at avg. $0.44$6K
BLTE
BELITE BIO, INC
Apr 9, 2026
Sale(S)
Direct
1.1K shares at avg. $180.43$198K
BLTE
BELITE BIO, INC
Mar 31, 2026
Award(A)
Stock Option (right to buy)
Direct
13.8K shares-

		Type	Shares	Price		Ownership
Sep 24, 2026	BLTE BELITE BIO, INC	In-the-Money(X)	13,796	$0.44	$6,051	Direct
Apr 9, 2026	BLTE BELITE BIO, INC	Sale(S)	1,100	$180.43	$198,473	Direct
Mar 31, 2026	BLTE BELITE BIO, INC	Award(A) Stock Option (right to buy)	13,796	-	-	Direct

1-3 of 3 transactions

About Chen Wan-Shan

Chen Wan-Shan (SEC CIK 0002001438) files insider reports with the SEC as Director of BELITE BIO, INC (BLTE).

Signal8 holds 4 ownership filings by Chen Wan-Shan (1 Form 3, 3 Form 4), filed between Mar 18, 2026 and Oct 30, 2026. Those filings report 3 transactions, from Mar 31, 2026 to Sep 24, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Chen Wan-Shan's filings is in SAN DIEGO, CA.

Recent filings by Chen Wan-Shan

Sep 24, 2026: Option exercise of BLTE shares (Form 4, code X).
Apr 9, 2026: Open-market sale of BLTE shares (Form 4, code S).
Mar 31, 2026: Grant or award of BLTE derivative securities (Form 4, code A).

Other insiders filing for BELITE BIO, INC (BLTE)

Chuang Hao-Yuan, Chief Financial Officer
Lin Yu-Hsin, Chief Executive Officer
Scholl Hendrik Peter, Chief Medical Officer
MATA NATHAN L., Chief Scientific Officer
Chen Xiao-Hui, Director
Longo John Michael, Director

How to read Form 4 transaction codes